Havana, Feb 22.- A few days after starting phase III of clinical trials with 42,600 volunteers, the Sovereign 02 vaccine that Cuba is developing today against Covid-19 marked informative spaces inside and outside the country.
Hopeful drug, safe technology, the first candidate in Latin America and extraordinary scientific achievement are some of the phrases that accompanied several articles about this candidate in media such as The New York Times, Business Insider, EuroNews and the British channel BBC.
Soberana 02 is trending worldwide because it is innovative, the only candidate for the conjugate vaccine platform in the world… Soon… another start, said Dagmar García, research director of the Finlay Vaccine Institute, leader of the project, on Twitter.
The Italian journalist, writer and television host Gianni Minà recently sent a letter to said institution in which she emphasizes that Cuba is the country of brotherhood and solidarity and this new vaccine, Soverana 02, is the proof.
Before the various headlines about this Cuban product, the ambassador of the Caribbean country in Argentina, Pedro Pablo Prada, highlighted that in just 48 hours six influential media around the world reviewed the successful advances of said candidate.
The president of Cuba, Miguel Díaz-Canel, highlighted the progress in the large-scale production of Soberana 02 yesterday and described it as another step towards the long-awaited immunization of Cubans.
For her part, Roselyn Martínez, deputy director of Industrial Operations of the Finlay Vaccine Institute, specified that the biopharmaceutical industry has already produced the first batch of 150,000 Soberana 02 bulbs and reported that the second group is being produced.
The director of the Institute, Vicente Vérez, explained in recent days that phase III of Soberana 02 is scheduled for next March 1 because it showed great safety in its study stages II A and II B, as well as a powerful immune response.
It also induces long-term memory of that immune response that, in addition to producing antibodies, makes them last, the expert pointed out.
He also highlighted that with this product the use of a third dose with reinforcing action is valued in order to induce viral neutralization immune response and a trial in pediatric patients.
It is a conjugate vaccine, in which the antigen of the virus, the receptor-binding domain (RBD), is chemically bound to tetanus toxoid, it has two formulations and the second of them was highly effective in animals.
The Caribbean island, the first in Latin America to present its own vaccines against Covid-19, also has three other proposals against Covid-19, Soberana 01 from the Finlay Institute and those prepared at the Abdala and Mambisa Center for Genetic Engineering and Biotechnology. (Text and photo: PL)